Matrix metalloproteinase 490 Subject

Daniels R, Gupta E, Kollias G, Huang MQ, Patel RN, Manning J, et al. Safety and pharmacokinetics of BMS-275291, a novel matrix metalloproteinase inhibitor in health subjects. Proc Anna Meet Am Soc Clin Oncol 2001 (abstract) submitted. 

Considerable interest has evolved over the past decade in the measurement of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloprotei-nases (TIMPs) in blood and urine as an aid in the diagnosis and prognosis of disease. The goal of this chapter is to provide a comprehensive review of the subject with the focus on potential future developments and applications of the technology. 

Both acute and chronic, experimentally-induced homocysteinaemia are associated with a proinflammatory, pro-oxidant state. In animal models, treatment with B vitamins suppresses vascular wall inflammation and reverses Hcy-mediated expression of adhesion molecules and matrix metalloproteinases in the vasculature (Hofmann et al. 2001). Clinical studies, however, have yielded conflicting results. Folic acid administration has been shown to reduce the release of chemokines from mononuclear cells in subjects with homocysteinaemia, but other studies have failed to document any effect of Hey lowering treatment on circulating levels of proinflammatory cytokines. 

Seliktar, D., R.M. Nerem, and Z.S. Galis, The role of matrix metalloproteinase-2 in the remodeling of cell-seeded vascular constructs subjected to cyclic strain. Ann Biomed Eng, 2001.29(11) 923-34. 

Chakir J, Boulay ME, Deschesnes F, Boulet LP. Allergen challenge (AC) increases matrix metalloproteinase-9 (MMP-9) in the sputum of allergic asthmatic (AA) subjects. Am J Respir Crit Care Med 163(5) A789. 

---